InsidersTradesSigma
Follow the 鹭燕医药 share price and the full directors' dealings record of the company, a publicly traded company based in China. Shares trade on the CN market, under the supervision of SSE / SZSE (CSRC). Operating in the Health Care sector, 鹭燕医药 has published 9 insider filings. Market capitalisation: €3.9bn. The latest transaction was disclosed on 28 November 2024 (Sale). Among the most active insiders: 雷鸣. Every trade is openly available.
9
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€831,192
9 ops.
Sell Volume
11Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 16,572 of 28,803 companies
47.7
score / 100
Value69
Quality26
FCF yld12%
Earn yld7.2%
EV/EBITDA12.6x
ROE8.3%
Gross mgn7.1%
Net mgn1.3%
Debt/EBITDA7.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 28 November 2024
Declarations9 total
9 of 9 declarations
About 鹭燕医药
鹭燕医药 is a company operating in the healthcare and pharmaceutical sector, listed on the XSHE market. It focuses on the development and distribution of pharmaceutical products.